Number of items: 103.
2024
Williamson, A., Houston, P., Paterson, J., Chalmers, A. J. , McLoone, P. , Fullerton, N., Foo, S. Y., James, A. and Nowicki, S.
(2024)
Dosimetric comparison of hippocampal sparing technologies in patients with low grade glioma.
Neuro-Oncology Advances,
(doi: 10.1093/noajnl/vdae131)
(Early Online Publication)
Lorimer, C., Mills, S., Chalmers, A. , Coombes, I., Thompson, G., Glendenning, J., Radon, M., Jones, C., Williamson, A. and Brock, J.
(2024)
Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER study.
Neuro-Oncology Practice, 11(4),
pp. 413-420.
(doi: 10.1093/nop/npae019)
(PMID:39006523)
Wakeham, K., Cooper, T., Rowbottom, C., Chalmers, A. J. , Price, P., Quinlan, S. and Spencer, K.
(2024)
Towards world-class radiotherapy in the UK: time for transformation.
Lancet Oncology, 25(4),
pp. 418-419.
(doi: 10.1016/S1470-2045(24)00103-7)
(PMID:38408465)
Jackson, M. R., Richards, A. R., Oladipupo, A.-B. A., Chahal, S. K., Caragher, S., Chalmers, A. J. and Gomez-Roman, N.
(2024)
ClonoScreen3D - a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma.
International Journal of Radiation Oncology, Biology, Physics,
(doi: 10.1016/j.ijrobp.2024.02.046)
(PMID:38493899)
(In Press)
Boele, F. et al.
(2024)
Inequalities in access to neuro-oncology supportive care and rehabilitation: a survey of healthcare professionals’ perspectives.
Neuro-Oncology Practice,
(doi: 10.1093/nop/npae023)
(Early Online Publication)
Derby, S. et al.
(2024)
Concurrent olaparib and radiation therapy in older patients with newly diagnosed glioblastoma: the phase 1 dose-escalation PARADIGM trial.
International Journal of Radiation Oncology, Biology, Physics, 118(5),
pp. 1371-1378.
(doi: 10.1016/j.ijrobp.2024.01.011)
(PMID:38211641)
Tesson, M., Stevenson, K., Karim, S. A., Nixon, C., Chalmers, A. J. , Sansom, O. J., O'Neill, E., Jones, K. and Morton, J. P.
(2024)
Targeted irradiation in an autochthonous mouse model of pancreatic cancer.
Disease Models and Mechanisms, 17(3),
dmm050463.
(doi: 10.1242/dmm.050463)
(PMID:38421046)
(PMCID:PMC10958199)
Derby, S. et al.
(2024)
Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial.
International Journal of Radiation Oncology, Biology, Physics,
(doi: 10.1016/j.ijrobp.2024.01.011)
(PMID:38211641)
(In Press)
Derby, S. et al.
(2024)
Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis.
Neuro-Oncology,
(doi: 10.1093/neuonc/noad210)
(PMID:37936324)
(Early Online Publication)
2023
Kouli, O. O., McLoone, P. , Morrison, D., Zaorsky, N. G. and Chalmers, A. J.
(2023)
Risk of stroke-specific mortality after radiotherapy in patients with primary brain tumours.
Clinical and Translational Radiation Oncology, 42,
100658.
(doi: 10.1016/j.ctro.2023.100658)
(PMID:37502698)
(PMCID:PMC10368762)
Verhaegen, F. et al.
(2023)
Roadmap for precision preclinical x-ray radiation studies.
Physics in Medicine and Biology, 68(6),
06RM01.
(doi: 10.1088/1361-6560/acaf45)
(PMID:36584393)
Grocutt, L., Rutherford, A., Caldwell, D., Wilkinson, C., Chalmers, A.J. , Dempsey, L., Kelly, C. and O'Cathail, S.M.
(2023)
The impact of COVID-19 on radiotherapy services in Scotland, UK: a population-based study.
Clinical Oncology, 35(2),
e227-e234.
(doi: 10.1016/j.clon.2022.11.018)
(PMID:36528474)
(PMCID:PMC9708615)
Koessinger, D. et al.
(2023)
Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasiveness.
Neuro-Oncology Advances, 5(1),
vdad067.
(doi: 10.1093/noajnl/vdad067)
(PMID:37334166)
(PMCID:PMC10276538)
2022
O'Cathail, S.M. and Chalmers, A.J.
(2022)
Integrating novel cancer therapies with radiation - illuminating the tunnel.
Clinical Oncology, 35(1),
pp. 38-41.
(doi: 10.1016/j.clon.2022.10.010)
(PMID:36333159)
Falcone, M. et al.
(2022)
Sensitisation of cancer cells to radiotherapy by serine and glycine starvation.
British Journal of Cancer, 127(10),
pp. 1773-1786.
(doi: 10.1038/s41416-022-01965-6)
(PMID:36115879)
(PMCID:PMC9643498)
Koessinger, A. L. et al.
(2022)
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics.
Cell Death and Differentiation, 29(10),
pp. 2089-2104.
(doi: 10.1038/s41418-022-01001-3)
(PMID:35473984)
(PMCID:PMC9525582)
McAleavey, P. G., Walls, G. M. and Chalmers, A. J.
(2022)
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
CNS Oncology, 11(2),
CNS86.
(doi: 10.2217/cns-2021-0015)
(PMID:35603818)
(PMCID:PMC9134931)
Willers, H., Krause, M., Faivre-Finn, C. and Chalmers, A.
(2022)
Targeting PARP for chemoradiosensitization: opportunities, challenges, and the road ahead.
International Journal of Radiation Oncology, Biology, Physics, 112(2),
pp. 265-270.
(doi: 10.1016/j.ijrobp.2021.10.142)
(PMID:34998527)
Jackson, M. R. et al.
(2022)
Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis.
International Journal of Radiation Oncology, Biology, Physics, 112(1),
pp. 197-211.
(doi: 10.1016/j.ijrobp.2021.08.029)
(PMID:34478832)
(PMCID:PMC8406661)
Aiyappa-Maudsley, R., Chalmers, A. J. and Parsons, J. L.
(2022)
Factors affecting the radiation response in glioblastoma.
Neuro-Oncology Advances, 4(1),
vdac156.
(doi: 10.1093/noajnl/vdac156)
(PMID:36325371)
(PMCID:PMC9617255)
Derby, S. J. , Chalmers, A. J. and Carruthers, R.
(2022)
Radiotherapy-poly(ADP-ribose) polymerase inhibitor combinations: progress to date.
Seminars in Radiation Oncology, 32(1),
pp. 15-28.
(doi: 10.1016/j.semradonc.2021.09.005)
(PMID:34861992)
Gutierrez-Quintana, R. , Walker, D. J. , Williams, K. J., Forster, D. M. and Chalmers, A. J.
(2022)
Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors?
Neuro-Oncology Advances, 4(1),
vdab190.
(doi: 10.1093/noajnl/vdab190)
(PMID:35118383)
(PMCID:PMC8807076)
2021
Birch, J. et al.
(2021)
Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM.
Research Square,
(doi: 10.21203/rs.3.rs-967109/v1)
(PMID:37936324)
Tsim, S. et al.
(2021)
Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases.
Journal of Thoracic Oncology, 16(10),
pp. 1705-1717.
(doi: 10.1016/j.jtho.2021.05.018)
(PMID:34116230)
(PMCID:PMC8514249)
Koessinger, A. L. et al.
(2021)
Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics.
bioRxiv,
(doi: 10.1101/2021.06.13.448232)
Nile, D. L., Rae, C. , Walker, D. J. , Canning Waddington, J., Vincent, I. , Burgess, K., Gaze, M. N., Mairs, R. J. and Chalmers, A. J.
(2021)
Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells.
Cancer and Metabolism, 9,
24.
(doi: 10.1186/s40170-021-00258-5)
(PMID:34011385)
(PMCID:PMC8136224)
Chalmers, A.J. and Carruthers, R.D.
(2021)
Radiobiology summaries: DNA damage and repair.
Clinical Oncology, 33(5),
pp. 275-278.
(doi: 10.1016/j.clon.2020.12.006)
(PMID:33341330)
Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J.
(2021)
Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease.
International Journal of Radiation Oncology, Biology, Physics, 109(4),
pp. 886-890.
(doi: 10.1016/j.ijrobp.2020.12.003)
(PMID:33309910)
(PMCID:PMC7726525)
Rulach, R. et al.
(2021)
An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer.
Advances in Radiation Oncology, 6(2),
100653.
(doi: 10.1016/j.adro.2021.100653)
(PMID:33851065)
(PMCID:PMC8022147)
Liu, Q. et al.
(2021)
Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types.
Science Translational Medicine, 13(580),
eabc4465.
(doi: 10.1126/scitranslmed.abc4465)
(PMID:33568520)
Al-mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Chalmers, A.J. and Holmes, W.M.
(2021)
Evaluating potential of multi-parametric MRI using co-registered histology: Application to a mouse model of glioblastoma.
Magnetic resonance imaging, 85,
pp. 121-127.
(doi: 10.1016/j.mri.2021.10.030)
(PMID:34687852)
Hadjiyiannakis, D., Dimitroyannis, D., Eastlake, L., Peedell, C., Tripathi, L., Simcock, R., Vyas, A., Deutsch, E. and Chalmers, A.J.
(2021)
Personal view: low-dose lung radiotherapy should be evaluated as a treatment for severe COVID-19 lung disease.
Clinical Oncology, 33(1),
e64-e68.
(doi: 10.1016/j.clon.2020.08.003)
(PMID:32829986)
(PMCID:PMC7427522)
2020
Hanna, C. et al.
(2020)
Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Neuro-Oncology, 22(12),
pp. 1840-1850.
(doi: 10.1093/neuonc/noaa104)
(PMID:32347934)
(PMCID:PMC7746945)
Koessinger, A. L., Koessinger, D., Stevenson, K., Cloix, C., Mitchell, L., Nixon, C., Gomez-Roman, N. , Chalmers, A. J. , Norman, J. C. and Tait, S. W.G.
(2020)
Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts.
Scientific Reports, 10,
15361.
(doi: 10.1038/s41598-020-72322-x)
(PMID:32958777)
(PMCID:PMC7506024)
Rae, C. , Fragkoulis, G. I. and Chalmers, A. J.
(2020)
Cytotoxicity and radiosensitizing activity of the fatty acid synthase inhibitor C75 is enhanced by blocking fatty acid uptake in prostate cancer cells.
Advances in Radiation Oncology, 5(5),
pp. 944-1005.
(doi: 10.1016/j.adro.2020.06.022)
(PMID:33083663)
(PMCID:PMC7557210)
Litchfield, K. et al.
(2020)
Representative sequencing: unbiased sampling of solid tumor tissue.
Cell Reports, 31(5),
107550.
(doi: 10.1016/j.celrep.2020.107550)
(PMID:32375028)
Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J.
(2020)
Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics.
International Journal of Radiation Oncology, Biology, Physics, 106(4),
pp. 867-877.
(doi: 10.1016/j.ijrobp.2019.11.029)
(PMID:31786278)
Gomez-Roman, N. , Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R. , Stevenson, K. H., Dongre, S. A. and Chalmers, A. J.
(2020)
Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ.
Molecular Cancer Therapeutics, 19(2),
pp. 575-589.
(doi: 10.1158/1535-7163.MCT-18-1320)
(PMID:31672763)
Chalmers, A.J. , Chan, C. and Sebag-Montefiore, D.
(2020)
CTRad 10 years on: from 10-point plan to top 10 achievements.
Clinical Oncology, 32(1),
pp. 9-12.
(doi: 10.1016/j.clon.2019.09.043)
(PMID:31543302)
2019
Beckta, J. M., Bindra, R. S. and Chalmers, A. J.
(2019)
Targeting DNA repair in gliomas.
Current Opinion in Neurology, 32(6),
pp. 878-885.
(doi: 10.1097/WCO.0000000000000760)
(PMID:31592790)
Chong, M. Y., Lorimer, C. F., Mehta, S., Ibrahim, E., Brock, J., McBain, C., McLoone, P. and Chalmers, A. J.
(2019)
An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?
CNS Oncology, 8(4),
CNS47.
(doi: 10.2217/cns-2019-0017)
(PMID:31818127)
(PMCID:PMC6974914)
Al-Mubarak, H., Vallatos, A. , Gallagher, L., Birch, J. , Gilmour, L., Foster, J., Chalmers, A.J. and Holmes, W.M.
(2019)
Stacked in-plane histology for quantitative validation of non-invasive imaging biomarkers: application to an infiltrative brain tumour model.
Journal of Neuroscience Methods, 326,
108372.
(doi: 10.1016/j.jneumeth.2019.108372)
(PMID:31348965)
Venkataramani, V. et al.
(2019)
Glutamatergic synaptic input to glioma cells drives brain tumour progression.
Nature, 573(7775),
pp. 532-538.
(doi: 10.1038/s41586-019-1564-x)
(PMID:31534219)
Palma, D. A. et al.
(2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
BMC Cancer, 19(1),
816.
(doi: 10.1186/s12885-019-5977-6)
(PMID:31426760)
(PMCID:PMC6699121)
Vallatos, A. , Al-Mubarak, H.F.I., Birch, J.L. , Gallagher, L., Mullin, J.M., Gilmour, L., Holmes, W.M. and Chalmers, A.J.
(2019)
Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region.
Journal of Magnetic Resonance Imaging, 50(2),
pp. 529-540.
(doi: 10.1002/jmri.26580)
(PMID:30569620)
Kokurewicz, K. et al.
(2019)
Focused very high-energy electron beams as a novel radiotherapy modality for producing high-dose volumetric elements.
Scientific Reports, 9,
10837.
(doi: 10.1038/s41598-019-46630-w)
(PMID:31346184)
(PMCID:PMC6658670)
Gomez-Roman, N. and Chalmers, A. J.
(2019)
Patient-specific 3D-printed glioblastomas.
Nature Biomedical Engineering, 3,
pp. 498-499.
(doi: 10.1038/s41551-019-0379-2)
(PMID:31148599)
Gobin, M. et al.
(2019)
A DNA repair and cell cycle gene expression signature in primary and recurrent glioblastoma: prognostic value and clinical implications.
Cancer Research, 79(6),
pp. 1226-1238.
(doi: 10.1158/0008-5472.CAN-18-2076)
(PMID:30674534)
Caragher, S., Chalmers, A. J. and Gomez-Roman, M.
(2019)
Glioblastoma's next top model: novel culture systems for brain cancer radiotherapy research.
Cancers, 11(1),
44.
(doi: 10.3390/cancers11010044)
(PMID:30621226)
(PMCID:PMC6356812)
Rutherford, A., Stevenson, K., Tulk, A. and Chalmers, A. J.
(2019)
Evaluation of four different small animal radiation plans on tumour and normal tissue dosimetry in a glioblastoma mouse model.
British Journal of Radiology, 92(1095),
20180469.
(doi: 10.1259/bjr.20180469)
(PMID:30362815)
(PMCID:PMC6541187)
2018
Birch, J. L. et al.
(2018)
A novel small-molecule inhibitor of MRCK prevents radiation-driven invasion in glioblastoma.
Cancer Research, 78(22),
pp. 6509-6522.
(doi: 10.1158/0008-5472.CAN-18-1697)
(PMID:30279244)
Sharma, R. A. et al.
(2018)
Clinical development of new drug–radiotherapy combinations.
Nature Reviews Clinical Oncology, 13(10),
pp. 627-642.
(doi: 10.1038/nrclinonc.2016.79)
(PMID:27245279)
Carruthers, R. D. et al.
(2018)
Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells.
Cancer Research, 78(17),
pp. 5060-5071.
(doi: 10.1158/0008-5472.CAN-18-0569)
(PMID:29976574)
(PMCID:PMC6128404)
Martinez-Zubiaurre, I., Chalmers, A. J. and Hellevik, T.
(2018)
Radiation-induced transformation of immunoregulatory networks in the tumor stroma.
Frontiers in Immunology, 9,
1679.
(doi: 10.3389/fimmu.2018.01679)
(PMID:30105016)
(PMCID:PMC6077256)
Martin, G. A. , Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P. , Chalmers, A. and Blyth, K. G.
(2018)
Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion.
BMJ Open Respiratory Research, 5(1),
e000293.
(doi: 10.1136/bmjresp-2018-000293)
(PMID:29862030)
(PMCID:PMC5976095)
Zmuda, F., Blair, A., Liuzzi, M. C., Malviya, G. , Chalmers, A. J. , Lewis, D., Sutherland, A. and Pimlott, S. L.
(2018)
An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent.
Journal of Medicinal Chemistry, 61(9),
pp. 4103-4114.
(doi: 10.1021/acs.jmedchem.8b00138)
(PMID:29630818)
(PMCID:PMC6007963)
Gray, E. et al.
(2018)
Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios.
BMJ Open, 8(5),
e017593.
(doi: 10.1136/bmjopen-2017-017593)
(PMID:29794088)
(PMCID:PMC5988134)
Holmes, W. M. , Vallatos, A. , Gilmour, L. and Chalmers, A. J.
(2018)
Multiple boli arterial spin labelling for high signal-to-noise rodent brain perfusion imaging.
Magnetic Resonance in Medicine, 79(2),
pp. 1020-1030.
(doi: 10.1002/mrm.26706)
(PMID:28516482)
Ashton, M. et al.
(2018)
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.
Clinical and Translational Radiation Oncology, 8,
pp. 45-49.
(doi: 10.1016/j.ctro.2017.11.004)
Fulton, B. et al.
(2018)
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Clinical and Translational Radiation Oncology, 8,
pp. 12-16.
(doi: 10.1016/j.ctro.2017.11.003)
Thompson, M. K., Poortmans, P., Chalmers, A. J. , Faivre-Finn, C., Hall, E., Huddart, R. A., Lievens, Y., Sebag-Montefiore, D. and Coles, C. E.
(2018)
Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?
British Journal of Cancer, 119,
pp. 389-407.
(doi: 10.1038/s41416-018-0201-z)
(PMID:30061587)
(PMCID:PMC6117262)
2017
Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J.
(2017)
Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes.
Clinical Oncology, 29(11),
pp. 739-747.
(doi: 10.1016/j.clon.2017.05.010)
(PMID:28807361)
Ashton, M., O'Rourke, N., Currie, S., Rimner, A. and Chalmers, A.
(2017)
The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review.
Radiotherapy and Oncology, 125(1),
pp. 1-12.
(doi: 10.1016/j.radonc.2017.08.003)
(PMID:28859932)
Bindra, R. S., Chalmers, A. J. , Evans, S. and Dewhirst, M.
(2017)
GBM radiosensitizers: dead in the water…or just the beginning?
Journal of Neuro-Oncology, 134(3),
pp. 513-521.
(doi: 10.1007/s11060-017-2427-7)
(PMID:28762004)
Gomez-Roman, N. , Stevenson, K., Gilmour, L., Hamilton, G. and Chalmers, A.
(2017)
A novel 3D human glioblastoma cell culture system for modeling
drug and radiation responses.
Neuro-Oncology, 19(2),
pp. 229-241.
(doi: 10.1093/neuonc/now164)
(PMID:27576873)
(PMCID:PMC5463789)
Paterson, C. et al.
(2017)
Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study.
Clinical and Translational Radiation Oncology, 2,
pp. 13-18.
(doi: 10.1016/j.ctro.2016.12.003)
Carruthers, R. and Chalmers, A. J.
(2017)
Improving the therapeutic ratio of radiotherapy by targeting the DNA damage response.
In: Tofilon, P. J. and Camphausen, K. (eds.)
Increasing the Therapeutic Ratio of Radiotherapy.
Series: Cancer drug discovery and development.
Humana Press: Cham, Switzerland, pp. 1-34.
ISBN 9783319408521
(doi: 10.1007/978-3-319-40854-5_1)
2016
Kaur, A. et al.
(2016)
PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells.
Cancer Research, 76(23),
pp. 7001-7011.
(doi: 10.1158/0008-5472.CAN-16-1134)
(PMID:27671680)
Tsim, S. et al.
(2016)
Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study.
BMJ Open, 6(11),
e013324.
(doi: 10.1136/bmjopen-2016-013324)
(PMID:27884852)
(PMCID:PMC5168514)
Harrow, S., Hanna, G.G., Faivre-Finn, C., McDonald, F. and Chalmers, A.
(2016)
The challenges faced in developing novel drug radiation combinations in non-small cell lung cancer.
Clinical Oncology, 28(11),
pp. 720-725.
(doi: 10.1016/j.clon.2016.08.004)
(PMID:27591000)
Lorimer, C. F., Saran, F., Chalmers, A. J. and Brock, J.
(2016)
Glioblastoma in the elderly - how do we choose who to treat?
Journal of Geriatric Oncology, 7(6),
pp. 453-456.
(doi: 10.1016/j.jgo.2016.07.005)
(PMID:27478132)
Yahyanejad, S. et al.
(2016)
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Oncotarget, 7(27),
pp. 41251-41264.
(doi: 10.18632/oncotarget.9275)
(PMID:27183910)
Chalmers, A. J.
(2016)
Science in focus: combining radiotherapy with inhibitors of the DNA damage response.
Clinical Oncology, 28(5),
pp. 279-282.
(doi: 10.1016/j.clon.2016.01.035)
(PMID:26920234)
Gomez-Roman, N. , McGregor, F., Chalmers, A. J. and Plumb, J.
(2016)
Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer.
Oncotarget, 7,
16.
(doi: 10.18632/oncotarget.7998)
(PMID:26967059)
(PMCID:PMC5008389)
Niyazi, M. et al.
(2016)
ESTRO-ACROP guideline 'target delineation of glioblastomas'.
Radiotherapy and Oncology, 118(1),
pp. 35-42.
(doi: 10.1016/j.radonc.2015.12.003)
(PMID:26777122)
2015
Tardito, S. et al.
(2015)
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.
Nature Cell Biology, 17(12),
pp. 1556-1568.
(doi: 10.1038/ncb3272)
(PMID:26595383)
(PMCID:PMC4663685)
Zmuda, F., Malviya, G. , Blair, A., Boyd, M., Chalmers, A. J. , Sutherland, A. and Pimlott, S. L.
(2015)
Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo.
Journal of Medicinal Chemistry, 58(21),
pp. 8683-8693.
(doi: 10.1021/acs.jmedchem.5b01324)
(PMID:26469301)
Ahmed, S., Carruthers, R. , Gilmour, L., Yildirim, S., Watts, C. and Chalmers, A.
(2015)
Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells.
Cancer Research, 75(20),
pp. 4416-4428.
(doi: 10.1158/0008-5472.can-14-3790)
(PMID:26282173)
Mac Leod, N. et al.
(2015)
F-18 FDG PET-CT influences target delineation when combined with standard CT-based radiotherapy planning in the palliative setting in malignant pleural mesothelioma; an exploratory study.
Reports of Radiotherapy and Oncology, 2(2),
e3999.
(doi: 10.17795/rro-3999)
Carruthers, R. and Chalmers, A.
(2015)
Combination of PARP inhibitors with clinical radiotherapy.
In: Curtin, N. J. and Sharma, R. A. (eds.)
PARP Inhibitors for Cancer Therapy.
Series: Cancer drug discovery and development, 5 (83).
Springer International Publishing, pp. 533-551.
ISBN 9783319141503
(doi: 10.1007/978-3-319-14151-0_23)
MacLeod, N. et al.
(2015)
Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial.
Journal of Thoracic Oncology, 10(6),
pp. 944-950.
(doi: 10.1097/JTO.0000000000000499)
(PMID:25654216)
Ichim, G. et al.
(2015)
Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death.
Molecular Cell, 57(5),
pp. 860-872.
(doi: 10.1016/j.molcel.2015.01.018)
(PMID:25702873)
(PMCID:PMC4352766)
Meisenberg, C., Gilbert, D. C., Chalmers, A. , Haley, V., Gollins, S., Ward, S. E. and El-Khamisy, S. F.
(2015)
Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.
Molecular Cancer Therapeutics, 14(2),
pp. 575-585.
(doi: 10.1158/1535-7163.MCT-14-0762)
(PMID:25522766)
Carruthers, R. , Ahmed, S. U., Strathdee, K., Gomez-Roman, N. , Amoah-Buahin, E., Watts, C. and Chalmers, A. J.
(2015)
Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase.
Molecular Oncology, 9(1),
pp. 192-203.
(doi: 10.1016/j.molonc.2014.08.003)
Blair, A., Zmuda, F., Malviya, G. , Chalmers, A. J. , Dewar, D. , Pimlott, S. L. and Sutherland, A.
(2015)
A novel 18F-labelled high affinity agent for PET imaging of the translocator protein.
Chemical Science, 6(8),
pp. 4772-4777.
(doi: 10.1039/C5SC01647A)
2014
Ajaz, M., Jefferies, S., Brazil, L., Watts, C. and Chalmers, A.
(2014)
Current and investigational drug strategies for glioblastoma.
Clinical Oncology, 26(7),
pp. 419-430.
(doi: 10.1016/j.clon.2014.03.012)
Mannino, M., Gomez-Roman, N. , Hochegger, H. and Chalmers, A. J.
(2014)
Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics.
Stem Cell Research, 13(1),
pp. 135-143.
(doi: 10.1016/j.scr.2014.05.001)
(PMID:24879067)
(PMCID:PMC4085484)
Yahyanejad, S., Granton, P. V., Lieuwes, N. G., Gilmour, L., Dubois, L., Theys, J., Chalmers, A. J. , Verhaegen, F. and Vooijs, M.
(2014)
Complementary use of bioluminescence imaging and contrast-enhanced micro-computed tomography in an orthotopic brain tumor model.
Molecular imaging, 13,
pp. 1-8.
(PMID:25743108)
Smalley, S., Chalmers, A. J. and Morley, S. J.
(2014)
mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.
Molecular Cancer, 13(144),
(doi: 10.1186/1476-4598-13-144)
2013
Hellevik, T., Pettersen, I., Berg, V., Bruun, J., Bartnes, K., Busund, T.-L., Chalmers, A. , Bremnes,, R. and Martinez-Zubiaurre, I.
(2013)
Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth.
Translational Oncology, 6(1),
pp. 66-74.
(doi: 10.1593/tlo.12349)
(PMID:23418618)
(PMCID:PMC3573655)
2012
Alagoz, M., Gilbert, D.C., El-Khamisy, S. and Chalmers, A.
(2012)
DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
Current Medicinal Chemistry, 19(23),
pp. 3874-3885.
(doi: 10.2174/092986712802002590)
Ford, E., Catt, S., Chalmers, A. and Fallowfield, L.
(2012)
Systematic review of supportive care needs in patients with primary malignant brain tumors.
Neuro-Oncology, 14(4),
pp. 392-404.
(doi: 10.1093/neuonc/nor229)
Gilbert, D.C., Chalmers, A.J. and El-Khamisy, S.F.
(2012)
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
British Journal of Cancer, 106(1),
pp. 18-24.
(doi: 10.1038/bjc.2011.498)
Hellevik, T. et al.
(2012)
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced.
Radiation Oncology, 7(59),
(doi: 10.1186/1748-717X-7-59)
2011
Mannino, M. and Chalmers, A. J.
(2011)
Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'?
Molecular Oncology, 5(4),
pp. 374-386.
(doi: 10.1016/j.molonc.2011.05.001)
Catt, S. L., Anderson, J. L., Chalmers, A. J. and Fallowfield, L. J.
(2011)
A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent.
Journal of Evaluation in Clinical Practice, 17(1),
pp. 1-6.
(doi: 10.1111/j.1365-2753.2009.01292.x)
2010
Chalmers, A. J. , Lakshman, M., Chan, N. and Bristow, R. G.
(2010)
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Seminars in Radiation Oncology, 20(4),
pp. 274-281.
(doi: 10.1016/j.semradonc.2010.06.001)
Chalmers, A. J.
(2010)
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Anti-Cancer Agents in Medicinal Chemistry, 10(7),
pp. 520-533.
(doi: 10.2174/187152010793498627)
Löser, D. A., Shibata, A., Shibata, A. K., Woodbine, L. J., Jeggo, P. A. and Chalmers, A. J.
(2010)
Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Molecular Cancer Therapeutics, 9(6),
pp. 1775-1787.
(doi: 10.1158/1535-7163.MCT-09-1027)
Chalmers, A.J.
(2010)
Evaluating novel radiation techniques for the treatment of cerebral metastases.
British Journal of Radiology, 83(986),
pp. 98-100.
(doi: 10.1259/bjr/15790337)
2009
Chalmers, A.J. , Ruff, E.M., Martindale, C., Lovegrove, N. and Short, S.C.
(2009)
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
International Journal of Radiation Oncology, Biology, Physics, 75(5),
pp. 1511-1519.
(doi: 10.1016/j.ijrobp.2009.07.1703)
Dungey, F.A., Caldecott, K.W. and Chalmers, A.J.
(2009)
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Molecular Cancer Therapeutics, 8(8),
pp. 2243-2245.
(doi: 10.1158/1535-7163.MCT-09-0201)
2008
Dungey, F.A., Löser, D.A. and Chalmers, A.J.
(2008)
Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential.
International Journal of Radiation Oncology, Biology, Physics, 72(4),
pp. 1188-1197.
(doi: 10.1016/j.ijrobp.2008.07.031)
This list was generated on Thu Oct 3 00:09:39 2024 BST.